

## Quanterix to Present at Cowen and Company 36th Annual Health Care Conference

**LEXINGTON, Mass. – March 8, 2016** — Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, announced that Kevin Hrusovsky, Executive Chairman and CEO, will present at the <u>Cowen and Company 36th Annual Health Care Conference</u> at the Boston Marriott Copley Place today at 5:30 p.m. ET in the MIT Room.

"Quanterix is in an increasingly strong position to create compelling value, not only for investors, but for the betterment of human health as a whole," said Hrusovsky. "Our technology continues to demonstrate the game-changing capabilities it has for both life sciences and diagnostics."

Hrusovsky will provide a corporate overview of Quanterix and his strategic vision for transforming healthcare. Quanterix is experiencing triple-digit growth and has received numerous industry awards and recognitions, including being named one of <u>Fast Company's Most Innovative Companies for 2016</u>, and winning the prominent <u>GE – NFL Head Health Challenge</u> which funds innovative technologies that detect early stage mild traumatic brain injuries. With a strong pipeline of new research for 2016, Quanterix has already been featured in over 50 distinguished scientific publications.

A link to Kevin's presentation can be found here: <a href="http://info.quanterix.com/watch-quanterix-jp-morgan-healthcare-presentation">http://info.quanterix.com/watch-quanterix-jp-morgan-healthcare-presentation</a>.

## **About Quanterix**

Quanterix is a leader in life sciences and high definition diagnostics with an innovative solution that revolutionizes the early detection of diseases including cancer, neurologic diseases such as CTE and concussions, heart disease, inflammatory disease and infectious disease. The Simoa™ technology provides a digital approach to immunoassays, delivering a 1,000-fold increase in sensitivity to access previously undetectable proteins, providing unprecedented capabilities for both research and clinical applications. For more information visit <a href="https://www.quanterix.com">www.quanterix.com</a>

###

## **Contacts:**

Nikki Festa & Caitlyn Keating PAN Communications 617-502-4300 guanterix@pancomm.com